SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001123292-24-000115
Filing Date
2024-04-23
Accepted
2024-04-23 14:59:24
Documents
3

Document Format Files

Seq Description Document Type Size
1 emerald13g.htm SC 13G 149050
2 image2.jpg GRAPHIC 40730
3 image3.jpg GRAPHIC 32519
  Complete submission text file 0001123292-24-000115.txt   251578
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Subject) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89290 | Film No.: 24864297
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O EMERALD BIOVENTURES, LLC 555 MADISON AVENUE, SUITE 11D NEW YORK NY 10022
Business Address C/O EMERALD BIOVENTURES, LLC 555 MADISON AVENUE, SUITE 11D NEW YORK NY 10022 (332) 237-4447
Emerald Bioventures, LLC (Filed by) CIK: 0002020620 (see all company filings)

IRS No.: 861870726 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G